High-resistance inspiratory muscle strength training, or IMST, can help strengthen your breathing muscles. Practicing it for ...
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...
RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...
MyChesCo on MSN
Inhibikase enrolls first patient in phase 3 PAH trial
WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) has enrolled the first patient in its Phase 3 clinical trial ...
In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...
Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in New Orleans, March 28 to 30. The ...
Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...
AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and ...
In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results